Iterum Therapeutics plc Q3 2025 Earnings Recap

ITRM Q3 2025 November 14, 2025

Get alerts when ITRM reports next quarter

Iterum Therapeutics reported steady initial progress in the commercialization of Orlynda, with early prescriptions showing positive traction among prescribers despite ongoing payer coverage challenges.

Earnings Per Share Miss

$-0.20 vs $-0.13 est.

-53.8% surprise

Market Reaction

1-Day -22.95%

5-Day -17.85%

30-Day -17.23%

See ITRM alongside your other holdings

Add to your portfolio — free

Key Takeaways

Over 280 prescriptions for Orlynda generated within the early weeks post-launch, with over 100 unique prescribers.
Around 40% of prescriptions have been filled through specialty pharmacy partners, indicating initial acceptance despite limited payer decisions.
Collaboration with major distributors McKesson and AmerisourceBergen underway to enhance accessibility for prescribers outside typical purchasing models.
Positive feedback from physicians highlights Orlynda's potential to treat uncomplicated urinary tract infections effectively, especially in cases of antibiotic resistance.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ITRM on AllInvestView.